Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 50 of the 53 references it cites were found in a registry or an index.
Abstract
The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists. The GLP-1 receptor agonists currently approved in the United States for the treatment of type 2 diabetes include exenatide (administered twice daily), liraglutide and lixisenatide (administered once daily), and the once-weekly agents exenatide extended-release, albiglutide, and dulaglutide. These agents have been shown to reduce A1C (by ∼0.8–1.6%), body weight (by ∼1–3 kg), blood pressure, and lipids. GLP-1 receptor agonists are associated with a low risk of hypoglycemia, and the most common adverse effects are gastrointestinal. Proper patient selection and education can assist in achieving positive treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The GI AE profile of semaglutide 2.4 mg in the STEP trials is consistent with previous observations with lower semaglutide doses and the established AE profile of GLP‐1RAs. 14 , 28 , 29”
From Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As higher incidences of GI AEs tend to be experienced with higher doses of GLP‐1RAs, gradual dose escalation and dose adjustment may help mitigate the impact of GI AEs in clinical practice. 29 , 30”
In the citing paper
“GLP-1-targeted therapies offer effective management of body weight and blood glucose levels, with underlying improvements to β-cell function and peripheral insulin sensitivity ( Zander et al., 2002 ; Hinnen, 2017 ).”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Hinnen, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“ings of the ELIXA outcomes study were neutral with respect to cardiovascular outcomes (31), whereas liraglutide demonstrated advantages versus placebo in the LEADER trial (32).”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Similar positive cardiovascular results were reported recently for semaglutide, an investigational GLP-1 receptor agonist administered QW (33).”
ResultMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Two incretin hormones have been identified: glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) (4).”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“O R G The incretin system has become an important target in the treatment of type 2 diabetes in recent years (1).”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“ings of the ELIXA outcomes study were neutral with respect to cardiovascular outcomes (31), whereas liraglutide demonstrated advantages versus placebo in the LEADER trial (32).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect is reduced in people with type 2 diabetes (6).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Research works printed but not linked: 2
- Johnson, 2014, Integrated phase 3 immunogenicity results for albiglutide, Diabetes, 63, A427
- Milicevic, 2015, Low incidence of anti-drug antibody in type 2 diabetes patients treated with once-weekly dulaglutide, Diabetes, 64, A292
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01710-0 · Cited by 297
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14551 · Cited by 200
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
“This drug was followed by the next generation of drugs with a pharmacokinetic profile allowing for once-daily (liraglutide, lixisenatide) and once-weekly injections (semaglutide, albiglutide and dulaglutide) [86].”
BackgroundSingh, A., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive Physiology · doi:10.1002/cph4.70003 · Cited by 163
Riyaphan, J., Pham, D.-C., Leong, M. K., & Weng, C.-F. (2021) · Biomolecules · doi:10.3390/biom11121877 · Cited by 162
“Vomit, diarrhea, gastrointestinal problems [46].”
Butyrate generated by gut microbiota and its therapeutic role in metabolic syndrome
Bridgeman, S. C., Northrop, W., Melton, P. E., Ellison, G., Newsholme, P., & Mamotte, C. D. S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105174 · Cited by 144
Chronotherapy for Hypertension
Bowles, N. P., Thosar, S. S., Herzig, M. X., & Shea, S. A. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0897-4 · Cited by 141
Sarma, S., & Palcu, P. (2022) · Obesity · doi:10.1002/oby.23563 · Cited by 133
“Any GLP-1 receptor agonist approved for human use by the Food and Drug Administration (FDA) or Health Canada was included: liraglutide, dulaglutide, semaglutide, exenatide, lixisenatide, and albiglutide [33].”
BackgroundTirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
“Antidrug antibodies have also been reported to varying extents with GLP-1 receptor agonists, again with little apparent clinical relevance.(109,110)”
BackgroundRehman, K., Haider, K., Jabeen, K., & Akash, M. S. H. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09549-6 · Cited by 126
Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment
Gieroba, B., Kryska, A., & Sroka‐Bartnicka, A. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102037 · Cited by 209
“GLP-1 and GLP-1 receptor agonists effectively treat T2DM by promoting glucose-dependent insulin secretion, inhibiting glucagon secretion, and displaying hypoglycemic properties effects [63].”
GLP‐1 agonists for obesity and type 2 diabetes in children: Systematic review and meta‐analysis
Chadda, K. R., Cheng, T. S., & Ong, K. K. (2020) · Obesity Reviews · doi:10.1111/obr.13177 · Cited by 111
“6 kg (depending on the drug regimen).(21) Unlike some of those reviews in adults, in children, we found little or no contribution of treatment duration to study-level differences in treatment effect, although our analysis was limited by the small number of studies in children.”
BackgroundSundaram, K., Teng, Y., Mu, J., Xu, Q., Xu, F., Sriwastva, M. K., Zhang, L., Park, J. W., Zhang, X., Yan, J., et al. (2024) · Small · doi:10.1002/smll.202308680 · Cited by 111
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review
Drummond, R. F., Seif, K. E., & Reece, E. A. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.08.024 · Cited by 110
Abushamat, L. A., Shah, P. A., Eckel, R. H., Harrison, S. A., & Barb, D. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.01.032 · Cited by 114
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96
“regions in the hypothalamus causing reductions in appetite and food intake and thereby promoting weight loss [18,19].”
BackgroundInfluentialToki, S., Newcomb, D. C., Printz, R. L., Cahill, K. N., Boyd, K. L., Niswender, K. D., & Peebles, R. S. (2021) · Allergy · doi:10.1111/all.14879 · Cited by 96
Richards, P., Thornberry, N. A., & Pinto, S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101175 · Cited by 92
Role of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases
Khemka, S., Reddy, A., Garcia, R. I., Jacobs, M., Reddy, R. P., Roghani, A. K., Pattoor, V., Basu, T., Sehar, U., & Reddy, P. H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102091 · Cited by 88
Parkinson's disease in women: Mechanisms underlying sex differences
Vaidya, B., Dhamija, K., Guru, P., & Sharma, S. S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173862 · Cited by 99
Porto, A. D., Casarsa, V., Colussi, G., Catena, C., Cavarape, A., & Sechi, L. A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.009 · Cited by 91
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lópes, R. D., Al‐Khalidi, H. R., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 83
Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74
Pharmacogenetics of Type 2 Diabetes—Progress and Prospects
Nasykhova, Y. A., Tonyan, Z. N., Mikhailova, A. A., Danilova, M. M., & Glotov, A. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186842 · Cited by 80
“Therefore, GLP1RA therapy overcomes the main limitation of native GLP1 and GIP [122].”
New Insights into the Structure and Function of Class B1 GPCRs
Cary, B. P., Zhang, X., Cao, J., Johnson, R. M., Piper, S. J., Gerrard, E. J., Wootten, D. L., & Sexton, P. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac033 · Cited by 77
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
GLP-1 agonists: A review for emergency clinicians
Long, B., Pelletier, J., Koyfman, A., & Bridwell, R. E. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.01.010 · Cited by 67
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Ismail, R., Bocsik, A., Katona, G., Gróf, I., Deli, M. A., & Csóka, I. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110599 · Cited by 66
“The worldwide prevalence of type 2 diabetes mellitus (T2DM) has been increasing dramatically and has become a serious issue at an alarming rate.”
BackgroundSignatures of metabolic diseases on spermatogenesis and testicular metabolism
Carrageta, D. F., Pereira, S., Ferreira, R. M., Monteiro, M. P., Oliveira, P. F., & Alves, M. G. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00866-y · Cited by 68
“Thanks to these attributes, GLP1 analogues were formulated for treating diabetes and obesity 76 .”
Aroda, V. R., Erhan, U., Jelnes, P., Meier, J. J., Abildlund, M. T., Pratley, R. E., Vilsbøll, T., & Husain, M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14990 · Cited by 71
“suppress appetite, slow gastric emptying and enhance satiety.(45) These mechanism-related effects should be better distinguished from true gastrointestinal distress and the negative sensation of nausea.”
BackgroundHamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 94
“This is crucial to fully realize the promise of these drugs in enhancing patient outcomes, while also lowering the cost of T2DM and obesity in healthcare systems [103,121].”
BackgroundEmerging diabetes therapies: Bringing back the β-cells
Basile, G., Qadir, M. M. F., Mauvais‐Jarvis, F., Vetere, A., Shoba, V. M., Modell, A. E., Pastori, R. L., Russ, H. A., Wagner, B. K., & Domínguez‐Bendala, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101477 · Cited by 62
Sarkar, S., & Brown, T. T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01382-8 · Cited by 59
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Xu, D., Nair, A., Sigston, C., Ho, C. L. B., Li, J., Yang, D.-Y. D., Liao, X., Chen, W., Kuang, M., Li, Y., et al. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/6820377 · Cited by 61
“Generally, the risk of hypoglycaemia in patients taking GLP-1 RAs alone was low, and similar across all GLP-1 RAs [66, 69].”
Sharma, A., Mah, M., Ritchie, R. H., & Blasio, M. J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108008 · Cited by 53
Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes
Wang, L., Volkow, N. D., Kaelber, D. C., & Xu, R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26327 · Cited by 51
Eid, L. E., Reynolds, C. A., Tomás, A., & Jones, B. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106411 · Cited by 57
Clarke, G. S., Page, A. J., & Eldeghaidy, S. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70027 · Cited by 55
“130 Several neuroimaging studies have explored how GLP-1 receptor agonists influence the brain activ - ity associated with appetite and satiety.”
BackgroundEmerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 53
“The glucose-dependent insulinotropic mechanism of GLP-1 RAs fundamentally transformed type 2 diabetes management by virtually eliminating hypoglycemia risk—a limitation that had constrained earlier antidiabetic therapies [58].”
Krisanapan, P., Suppadungsuk, S., Sanpawithayakul, K., Thongprayoon, C., Pattharanitima, P., Tangpanithandee, S., Mao, M. A., Miao, J., & Cheungpasitporn, W. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae018 · Cited by 49
Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)
Rehani, P. R., Iftikhar, H., Nakajima, M., Tanaka, T., Jabbar, Z., & Rehani, R. (2019) · Journal of Diabetes Research · doi:10.1155/2019/4267357 · Cited by 55
“However, liraglutide, in specific instances, has been shown to reduce adverse cardiovascular events [25, 27, 28].”
BackgroundA 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A. (2021) · Medicina · doi:10.3390/medicina57070669 · Cited by 43
“GLP-1 RAs increase insulin secretion and inhibit the glucagon action in a glucose-dependent manner, making it less likely for hypoglycemia [62].”
BackgroundSavarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Concentrated insulins: Clinical update of therapeutic options
Umpierrez, G. E., Holt, E. H., Einhorn, D., & McGill, J. B. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0607 · Cited by 44
Barritt, A. S., Marshman, E., & Noureddin, M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16794 · Cited by 46
Lupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17856 · Cited by 44
“Patients should be educated on side effects and recommended to eat smaller meals and stop when feeling full 11,140 Treatment goals should be individualised for each patient; how - ever, lifestyle modifications leading to 5%–10% weight loss including increasing physical activity and/or a low-calorie…”
BackgroundFrias, J. P., Choi, J., Rosenstock, J., Popescu, L., Niemoeller, E., Muehlen-Bartmer, I., & Baek, S. (2022) · Diabetes Care · doi:10.2337/dc21-2656 · Cited by 38
“Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are currently recommended as the first injectable agent for patients with type 2 diabetes inadequately controlled on oral glucose-lowering medications (1,2) because of their glycemic efficacy, low risk of hypoglycemia, and favorable effects on body weight (3).”
BackgroundAlorfi, N. M., & Algarni, A. S. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s374741 · Cited by 53
Yao, M., Zhang, J., Zhi-hong, L., Bai, X., Ma, J., & Li, Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.630962 · Cited by 47
“Incretin system and particularly glucagon-like peptide 1 (GLP-1) because of its glucose-lowering effects has become an important target in therapeutic strategies of type 2 diabetes (T2D).”
BackgroundInfluentialManagement of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia
Goncalves, M. D., & Farooki, A. (2022) · Integrative Cancer Therapies · doi:10.1177/15347354211073163 · Cited by 37
Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity
Jensterle, M., & Janež, A. (2021) · Hormone Research in Paediatrics · doi:10.1159/000521264 · Cited by 40
“Most important for the weight-reducing properties is activation of neural pathways causing reductions in appetite-regulating regions in the hypothalamus causing reductions in appetite and food intake and thereby promoting weight loss [26, 27].”
Hypoglycemic natural products with in vivo activities and their mechanisms: a review
Ma, W., Xiao, L., Liu, H., & Hao, X. (2022) · Food Science and Human Wellness · doi:10.1016/j.fshw.2022.04.001 · Cited by 38
Yang, Y.-S., Chen, H.-H., Huang, C.-N., Hsu, C. Y., Hu, K.-C., & Kao, C.-H. (2022) · Diabetes Care · doi:10.2337/dc21-1993 · Cited by 35
Abiola, J. O., Oluyemi, A. A., Idowu, O. T., Oyinloye, O. M., Ubah, C. S., Owolabi, O. V., Somade, O. T., Onikanni, S. A., Ajiboye, B. O., Osunsanmi, F. O., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060736 · Cited by 40
“Research Research suggests that GLP-1 analogs may bene fi t type 1 diabetes patients by improving hemoglobin A1c levels and promoting weight loss. that GLP-1 analogs may benefit type 1 diabetes patients However, high costs and tolerability issues remain barriers to broader use [68–70].”
BackgroundSemaglutide-associated kidney injury
Begum, F., Chang, K., Kapoor, K., Vij, R. S., Phadke, G. M., Hiser, W. M., Wanchoo, R., Sharma, P., Sutaria, N., & Jhaveri, K. D. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae250 · Cited by 37
“Glucagon-like peptide-1 receptor agonists ( GLP-1RAs) are incretin analogues that potentiate glucose-dependent insulin excretion, delay gastric emptying, suppress glucagon secretion and reduce appetite [1 ].”
BackgroundMahboob, A., Senevirathne, D. K. L., Paul, P., Nabi, F., Khan, R. H., & Châari, A. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.038 · Cited by 39
Nguyen, T. T. N., Choi, H., & Jun, H.-S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00090 · Cited by 34
“Glucagon-like peptide-1 (GLP-1), an incretin hormone produced by the intestinal mucosa, is secreted after meal consumption and stimulates insulin secretion (Hinnen, 2017).”
BackgroundSingh, S. T., Garg, A., Tantry, U. S., Bliden, K. P., Gurbel, P. A., & Gulati, M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102403 · Cited by 38
Shiju, R., Akhil, A., Thankachan, S., Tuomilehto, J. O., Arouj, M. A., & Bennakhi, A. (2022) · Journal of Diabetes Research · doi:10.1155/2022/3846253 · Cited by 40
“Several drugs in this class have been developed [64].”
BackgroundPostbariatric surgery hypoglycemia: Nutritional, pharmacological and surgical perspectives
Rossini, G., Risi, R., Monte, L., Sancetta, B. M., Quadrini, M., Ugoccioni, M., Masi, D., Rossetti, R., D’Alessio, R., Mazzilli, R., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3750 · Cited by 37
“101 Considering that patients with PBH show larger insulin and incretin responses to meal ingestions 27 and the ability of GLP ‐ 1 analogues to stabilise glycaemia without leading hypoglycemia in patients with diabetes, 101 it has been hypothesised that GLP1 analogues may be useful to treat PBH.…”
BackgroundResultGo Big or Go Home: Obesity and Total Joint Arthroplasty
Blankstein, M., Browne, J. A., Sonn, K. A., Ashkenazi, I., & Schwarzkopf, R. M. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.07.001 · Cited by 34
Albarado-Ibáñez, A., Arroyo-Carmona, R. E., Sánchez-Hernández, R., Ramos-Ortiz, G., Frank, A., García-Gudiño, D., & Torres-Jácome, J. (2019) · Journal of Diabetes Research · doi:10.1155/2019/5157024 · Cited by 33
“For this reason, the development of an animal model like cDM with pharmacological chronic therapy of GLP-1 and monitoring your HRV would improve macro- and microvascular side effects inclusive of fatal cardiovascular events [27].”
MethodDipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies
Bayanati, M., Rabbani, M. I. M., Kabiri, S. S., Sadegh, B. M. M., Rezaee, E., & Tabatabai, S. A. (2024) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-151581 · Cited by 36
Mirza, A. C., Panchal, S. S., Allam, A. A., Othman, S. I., Satia, M., & Mandhane, S. N. (2022) · Molecules · doi:10.3390/molecules27196722 · Cited by 32
“Low levels of glucagon-like peptide-1 (GLP-1) content in the jejunum, ileum, and colon were reported in nSTZ diabetic rats [82]; GLP-1 deficiency increases appetite, cell apoptosis, hepatic gluconeogenesis, and hepatic and muscular insulin resistance while decreasing insulin secretion, cell proliferation, and satiety…”
BackgroundTGR5 agonists for diabetes treatment: a patent review and clinical advancements (2012-present)
Bhimanwar, R. S., & Mittal, A. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.1994551 · Cited by 31
“Furthermore, GLP-1 agonists, such as Exenatide [7], are also co-administered with DDP-IV inhibitors to decrease glucagon release and stimulate glucose metabolism.”
BackgroundFrías, J. P., Lee, M. L., Carter, M. M., Ebel, E. R., Lai, R., Rikse, L., Washington, M. E., Sonnenburg, J. L., & Damman, C. J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14967 · Cited by 32
“Butyrate also stimulates glucagon-like peptide-1 release from intestinal L-cells, enhancing insulin secretion, modulating gastric emptying and, via central mechanisms, reducing appetite.(46,47) Recent epidemiological and interventional trials have also suggested RS and butyrate reduce blood pressure via proposed anti-…”
BackgroundKenakin, T. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00958-9 · Cited by 35
“GLP-1 receptor agonists are used in diabetes therapy to potentiate insulin release in response to food consumption, but nausea and/or desensitization have been observed with such drugs 122,123 because of constant direct activation of GLP-1 receptors.”
Glucagon‐like peptide‐1 receptor agonists in the era of COVID ‐19: Friend or foe?
Belančić, A., Kresović, A., & Dijan, M. (2021) · Clinical Obesity · doi:10.1111/cob.12439 · Cited by 32
“6%.(9) Besides substantial glucose-lowering effect, it Abbreviations: ACE-2, angiotensin converting enzyme-2; BMI, body mass index; COVID-19, Coronavirus disease 2019; FBG, fasting blood glucose; GLP-1RA, glucagon-like peptide-1 receptor agonist; LPS, lipopolysaccharide; NF-ĸb, nuclear factor-ĸB; SARS CoV-2, severe ac…”
BackgroundKrisanapan, P., Sanpawithayakul, K., Pattharanitima, P., Thongprayoon, C., Miao, J., Mao, M. A., Suppadungsuk, S., Tangpanithandee, S., Craici, I. M., & Cheungpasitporn, W. (2024) · Diseases · doi:10.3390/diseases12010014 · Cited by 36
“Given that GLP-1RAs stimulate insulin release in a glucose-dependent manner, its effectiveness may not be apparent in populations with well-controlled blood glucose [9,15,50].”
BackgroundChou, W.-L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105693 · Cited by 32
Tilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 32
“Furthermore, their action of increasing insulin production and lowering glucagon action is tailored in a glucose‐dependent manner, thus posing a low risk of hypoglycemia and making them one of the most effective and safe options when a more intensive antidiabetic treatment is required (30).”
BackgroundPeralta, F. G., & Abreu, C. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s165372 · Cited by 31
“reducing fat content may reduce the incidence of nausea and vomiting.(37) If gastrointestinal side effects are observed, dose”
BackgroundMitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Yip, J., Chiang, G. S. H., Lee, I. C. J., Lehming-Teo, R., Dai, K., Dongol, L., Wang, L. Y.-T., Teo, D. W. X., Seah, G. T., & Lehming, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010364 · Cited by 31
“SGLT2 inhibitors inhibit the function of the SGLT2 receptor, thereby obstructing the reabsorption of glucose in the kidney’s proximal tubule [418].”
Yang, Y. H., Zhou, Y., Wang, Y., Wei, X., Wu, L., Wang, T., & Ma, A. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01551-3 · Cited by 30
Majdpour, D., Tsoukas, M. A., Yale, J., Fathi, A. E., Rutkowski, J., René, J., Garfield, N., Legault, L., & Haidar, A. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.02.002 · Cited by 29
Neuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 30
Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease
Mahalingam, S., Bellamkonda, R., Arumugam, M. K., Perumal, S. K., Yoon, J., Casey, C. A., Kharbanda, K. K., & Rasineni, K. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115613 · Cited by 30
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus
Sharma, P., Singh, S., Thakur, V., Sharma, N., & Grewal, A. S. (2021) · Obesity Medicine · doi:10.1016/j.obmed.2021.100329 · Cited by 33
Wilson, P. R., Bridges, K. H., & Wilson, S. H. (2023) · A&A Practice · doi:10.1213/xaa.0000000000001712 · Cited by 30
Stretton, B., Kovoor, J., Bacchi, S., Chang, S., Ngoi, B., Murray, T., Bristow, T. C., Heng, J., Gupta, A., Ovenden, C., et al. (2023) · Internal Medicine Journal · doi:10.1111/imj.16126 · Cited by 26
Levidy, M. F., Vatsia, S. K., Gohel, N., Rowe, N. D., Kirchner, G. J., DeMedal, S., & Mason, M. (2025) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-24-01284 · Cited by 27
Elhassan, M. M., Mahmoud, A. M., Hegazy, M. A. M., & Mowaka, S. (2021) · Chemical Papers · doi:10.1007/s11696-021-01646-3 · Cited by 26
“This peptide is one of the incretin hormones secreted by the intestinal mucosa in response to meals and enhances the insulin secretion, so by inhibiting its breakdown, this will lead to a decrease in blood glucose level (Hinnen 2017).”
BackgroundMechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Tommerdahl, K. L., Nadeau, K. J., & Bjornstad, P. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.001 · Cited by 29
Wong, S. Y., Lee, A. R. Y. B., Sia, A. H. J., Wo, Y. J., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Ong, C. C., Teo, L., Yeo, T., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07360-w · Cited by 30
“Beyond its glucose-lowering and weight loss effects [2, 3], GLP-1 and GLP-1RAs Shi Yin Wong and Ainsley Ryan Yan Bin Lee contributed equally to this work. have shown effects on the cardiovascular system, including increasing glucose uptake by the myocardium [4], inhibiting the angiotensin II and…”
Smith, I., Hardy, E., Mitchell, S., & Batson, S. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s392952 · Cited by 39
Polymer-Based Nanostructures for Pancreatic Beta-Cell Imaging and Non-Invasive Treatment of Diabetes
Behzadifar, S., Barras, A., Plaisance, V., Pawlowski, V., Szunerits, S., Abderrahmani, A., & Boukherroub, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041215 · Cited by 27
“GLP-1Ras improve glucose-induced insulin secretion in similar mechanisms as GLP-1 does [133,134].”
BackgroundOptimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach
Isaacs, D. M., Kruger, D. F., & Spollett, G. R. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0016 · Cited by 26
“To mitigate GI side effects, it is recommended to adopt a dose-titration strategy (83,84), starting treatment with 3 mg oral semaglutide (13).”
BackgroundCholine‐Geranate Deep Eutectic Solvent Improves Stability and Half‐Life of Glucagon‐Like Peptide‐1
Agatemor, C., Brown, T. D., Gao, Y., Ohmori, N., Ibsen, K. N., & Mitragotri, S. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000180 · Cited by 29
Górriz, J. L., Romera, I., Cobo, A., O’Brien, P. D., & Merino-Torres, J. F. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01198-5 · Cited by 31
“glucose-lowering agents, including SGLT2i, when glycemic control is not achieved [75, 76].”
BackgroundChrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 26
“Agonists for incretin receptors have already shown efficacy for the treatment of T2DM [17] while they concurrently exert clinically meaningful benefits for the cardiovascular and renal systems [18].”
BackgroundTerenzi, D. C., Trac, J. Z., Teoh, H., Gerstein, H. C., Bhatt, D. L., Al-Omran, M. A., Verma, S., & Hess, D. A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.03.006 · Cited by 29
Unlocking Longevity with GLP-1: A Key to Turn Back the Clock?
Chavda, V. P., Balar, P. C., Vaghela, D. A., & Dodiya, P. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108028 · Cited by 24
Semaglutide “Ozempic” Face and Implications in Cosmetic Dermatology
Montecinos, K., Kania, B., & Goldberg, D. J. (2024) · Dermatological Reviews · doi:10.1002/der2.70003 · Cited by 25
“When blood glucose levels are elevated, semaglutide stimulates glucose ‐ dependent insulin secretion from pancreatic β ‐ cells to maintain glucose homeostasis [14, 15].”
Metadata
- Authors
- Hinnen, D.
- Affiliations
- University of Colorado Health (US)
- Corresponding author
- Hinnen, Deborah
- ORCID
- Hinnen, Deborah
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2017-08-01
- Volume
- 30
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- PMC
- PMC5556578
- OpenAlex
- W2592545469
- Cited by
- 394
- References
- 53
- Citations by year
- 2026: 23 · 2025: 71 · 2024: 59 · 2023: 57 · 2022: 53 · 2021: 59 · 2020: 46 · 2019: 22 · 2018: 3 · 2017: 1
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Spectrum (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- AstraZeneca
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, incretin system, exenatide, liraglutide, lixisenatide, exenatide extended-release, albiglutide, dulaglutide, glycemic control, weight loss, hypoglycemia risk, gastrointestinal adverse effects, patient selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.